Yahoo Canada Web Search

Search results

1. www.ncbi.nlm.nih.gov › pmc › articlesDevelopment of a Multi-Biomarker Disease Activity Test for...

   www.ncbi.nlm.nih.gov › pmc › articles

   Apr 9, 2013 · We applied a multi-step development process using multiple diverse cohorts to prioritize biomarkers of disease activity and develop such a multi-biomarker disease activity (MBDA) score for the assessment of RA disease activity.

   • Author: Michael Centola, Guy Cavet, Yijing Shen, Saroja Ramanujan, Nicholas Knowlton, Kathryn A. Swan, Mary ...
   • DOI: 10.1371/journal.pone.0060635

   • Publish Year: 2013
   • Publication: PLoS One. 2013; 8(4): e60635.

2. pubmed.ncbi.nlm.nih.gov › 23585841Development of a multi-biomarker disease activity test for ...

   pubmed.ncbi.nlm.nih.gov › 23585841

   Apr 9, 2013 · Objectives: To develop a multi-biomarker disease activity (MBDA) test for rheumatoid arthritis. Methods: Candidate serum protein biomarkers were selected from extensive literature screens, bioinformatics databases, mRNA expression and protein microarray data.

   • Author: Michael Centola, Guy Cavet, Yijing Shen, Saroja Ramanujan, Nicholas Knowlton, Kathryn A. Swan, Mary ...

   • Publish Year: 2013

3. Images

   • 
   • 
   • 
   • 

   View all

4. arthritis-research.biomedcentral.com › articles › 10The multi-biomarker disease activity test for assessing ...

   arthritis-research.biomedcentral.com › articles › 10

   • Cached

   • Camera-Ii Clinical Study Procedures and Summary of Results
   • The MBDA Score
   • Multiple Biomarker-Based Disease Activity Assessment in Camera-Ii
   • Statistical Analyses

   The design, intervention, and main analyses of the CAMERA-II study are reported in detail elsewhere . To summarize, CAMERA-II was a 2-year, prospective, randomized, placebo-controlled, double-blind multicenter tight control and treat-to-target (remission) strategy trial among patients with early RA (< 1 year since diagnosis). Patients were 18 years...

   See full list on arthritis-research.biomedcentral.com

   The development and validation of the MBDA score are reported in detail elsewhere [24, 25]. In short, 130 candidate biomarkers were tested in feasibility studies, of which 12 were selected for final algorithm development and validation. The biomarker selection and algorithm were optimized to maximize the strength of the association of the MBDA scor...

   See full list on arthritis-research.biomedcentral.com

   MBDA biomarkers were evaluated in serum samples obtained at baseline and at 1, 2, 3, 4, 5, 6, 9, and 12 months. Numbers of samples available for the present study varied between time points, based on patient compliance and the volume of available sample. Of 104 patients in CAMERA-II for whom baseline sera were available for MBDA testing, MBDA score...

   See full list on arthritis-research.biomedcentral.com

   To evaluate changes from baseline for DAS28 and MBDA score and comparisons of change in DAS28 or MBDA score over time between patients treated with the MTX+pred or MTX+plac strategy, a ttest was performed for each time point evaluated. Association between change from baseline to 12 months for DAS28 and MBDA score was assessed using Spearman’s rank ...

   See full list on arthritis-research.biomedcentral.com

   • Author: M S Jurgens, M Safy-Khan, M J H de Hair, J W J Bijlsma, P M J Welsing, J Tekstra, F P J G Lafeber, E...

   • Publish Year: 2020

5. arthritis-research.biomedcentral.com › articles › 10Validation of the adjusted multi-biomarker disease activity ...

   arthritis-research.biomedcentral.com › articles › 10

   • Cached

   Jan 4, 2021 · The multi-biomarker disease activity (MBDA) test measures 12 serum protein biomarkers to quantify disease activity in RA patients. A newer version of the MBDA score, adjusted for age, sex, and adiposity, has been validated in two cohorts (OPERA and BRASS) for predicting risk for radiographic progression.

   • Author: Jeffrey R. Curtis, Michael E. Weinblatt, Nancy A. Shadick, Cecilie H. Brahe, Mikkel Østergaard, Mere...

   • Publish Year: 2021

6. pubmed.ncbi.nlm.nih.gov › 36575983Multibiomarker disease activity score: an objective tool for ...

   pubmed.ncbi.nlm.nih.gov › 36575983

   Jun 1, 2023 · Objectives: The multibiomarker disease activity (MBDA) score is an objective tool for monitoring disease activity in RA. Here we report a systematic review and meta-analysis of the clinical value of the MBDA score in RA.

7. arthritis-research.biomedcentral.com › articles › 10The multi-biomarker disease activity score tracks response to ...

   arthritis-research.biomedcentral.com › articles › 10

   • Cached

   Nov 20, 2018 · A multi-biomarker disease activity (MBDA) score has been validated as an objective measure of disease activity in rheumatoid arthritis (RA) and shown to track response to treatment with several disease-modifying anti-rheumatic drugs (DMARDs).

8. People also ask

   What is the multi-biomarker disease activity (MBDA) test for rheumatoid arthritis (RA)?

   • The multi-biomarker disease activity (MBDA) test measures 12 serum protein biomarkers to quantify disease activity in RA patients. A newer version of the MBDA score, adjusted for age, sex, and adiposity, has been validated in two cohorts (OPERA and BRASS) for predicting risk for radiographic progression.

   Validation of the adjusted multi-biomarker disease activity score as a

   arthritis-research.biomedcentral.com/articles/10.1186/s13075-020-02389-4

   See all results for this question

   What is a multi-biomarker disease activity (MBDA) blood test?

   • The multi-biomarker disease activity (MBDA) blood test measures 12 biomarkers relevant to the pathophysiology of RA to provide an objective measure of RA disease activity. It uses a validated algorithm combining the biomarker concentrations to generate an integer score on a scale of 1 to 100 [ 22, 23, 24, 25 ].

   The multi-biomarker disease activity test for assessing response to

   arthritis-research.biomedcentral.com/articles/10.1186/s13075-020-02293-x

   See all results for this question

   Do multi-biomarker statistical models outperform individual biomarkers at estimating disease activity?

   • Multi-biomarker statistical models outperformed individual biomarkers at estimating disease activity. Biomarker-based scores were significantly correlated with DAS28-CRP and could discriminate patients with low vs. moderate/high clinical disease activity.

   Development of a multi-biomarker disease activity test for rheumatoid …

   pubmed.ncbi.nlm.nih.gov/23585841/

   See all results for this question

   How many MBDA biomarkers are there?

   • The 12 MBDA biomarkers could be grouped into 4 categories of response profiles, with significant responses for 4 biomarkers during the MTX+plac strategy and 9 biomarkers during the MTX+pred strategy. MBDA tracked treatment response in CAMERA-II similarly to DAS28.

   The multi-biomarker disease activity test for assessing response to

   arthritis-research.biomedcentral.com/articles/10.1186/s13075-020-02293-x

   See all results for this question

9. www.ncbi.nlm.nih.gov › pmc › articlesUptake and Clinical Utility of the Multi-Biomarker Disease ...

   www.ncbi.nlm.nih.gov › pmc › articles

   The clinical utility of the multi-biomarker disease activity (MBDA) test for rheumatoid arthritis (RA) management has been understudied in routine care in the U.S. Methods Using 2011–2015 Medicare data, we linked each RA patient to their MBDA test result.